Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9177647 | 0.86 | — | — | |
| SCHEMBL89771 | 0.82 | — | — | |
| SCHEMBL781345 | 0.80 | TACR1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL4537729 | 0.79 | — | — | |
| SCHEMBL21855942 | 0.77 | — | — | |
| SCHEMBL12453906 | 0.77 | — | — | |
| SCHEMBL629022 | 0.77 | — | — | |
| SCHEMBL23938069 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL56175 | 0.75 | — | — | |
| SCHEMBL20721137 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2616464-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | Mallinckrodt LLC (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037309-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7138397-B2 | Nitrogenous 5-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | SNRPD1, SNRPD2, SNRPA1 | SLC6A2 80/4885SLC6A4 47/4885SLC6A3 64/4885 |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | SLC6A2 773/4885SLC6A4 1684/4885SLC6A3 2289/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | SLC6A2 744/4885SLC6A4 1628/4885SLC6A3 2308/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | SLC6A2 891/4885SLC6A4 1985/4885SLC6A3 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.